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Proteins are made based on a DNA sequence template and fold 
into distinctive shapes or conformations.  Amyloids are proteins 
that can fold into a normal form and an abnormal form.  Prions 
are infectious amyloids that can further cause normally-folded 
versions to assume the amyloid shape.  Prions are present in 
many eukaryotes including humans, cows, sheep, and the 
baker’s yeast, Saccharomyces cerevisiae, among other 
species.  Yeast has several prion proteins including Ure3 and 
Sup35, the focus of this study.  Yeast prions are usually Q and N 
rich and like all amyloids, are composed of β-sheets.  It has been 
long appreciated that the Sup35 protein in yeast has substantial 
β-sheet structure in its N terminal “prion domain” when in its 
amyloid form.  However, the exact dimensions or interactions of 
the β-strands within the β-sheets are poorly 
understood.  Furthermore, there are few hydrophobic and 
charged amino acids residues in this region.  In this study we are 
testing the effect of adding one lysine amino acid (a charged 
amino acid) at several sites in Sup35 on the likelihood of prion 
formation and  stability, with the goal of helping to map β-sheet 
formation in the S. cerevisiae Sup35 prion protein.  
To study effects of mutation on β-sheet formation in the Sup35 protein, experiments 
were conducted in a strain of yeast expressing a “super-prion-forming” SUP35 gene. 
  
This SUP35 variant was subjected to 3 additional point mutations within the prion 
forming domain, adding the charged amino acid Lysine (K) at three distinct locations.   
  
PCR-based mutagenesis was employed to generate a full-length “2-piece” PCR product 
encoding mutated versions of the prion domain of SUP35.   
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These mutant PCR products were transformed into a prion-negative yeast strain and 
colonies were selected on the basis of nutritional markers (LEU2).  PCR was employed 
to amplify the SUP35 gene from each clone, followed by DNA sequencing by Genewiz, 
Inc. (New Jersey). 
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Figure 1. From left to right, 500 base pair ladder, construct 20,  
construct 25. This is the final PCR before transformation.  
The lower bands of construct 20 and 25 were cut out, purified and  
used in the transformation process. 
 
 
 
Figure 2. Yeast with a successful transformation of  
construct 25 plated on a sc-leu plate. Colonies from  
this and the other plates were picked, pre-amplified by  
PCR in the SUP35 gene region, and were sent off to  
be sequenced. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Representative DNA sequencing results from a single white colony from 
construct 25. The red arrow indicates where the sequence for the Sup35 gene begins, 
indicating the plasmid was successfully integrated into the SUP35 gene. However, 
despite the successful transformation, none of the yeast constructs sequenced 
contained the intended mutation in their given sites. 
 
 
 
 
 
 
 
 
None of the selected yeast colonies sequenced contained the 
intended lysine insertions; however, different colonies from the 
same yeast plates could be correct and should be evaluated. 
 
If those yeast colonies do have the mutation we could then use 
those colonies to assess the different properties each mutation 
has on prion properties of the Sup35 protein.  We intend to create 
versions with multiple insertions as well. 
 
If we do not find any colonies with the indicated mutations we 
could either start over making the mutants or design lysine 
insertions in different locations. Similarly we could try making 
constructs with an amino acid other than lysine.  For example, we 
have already acquired reagents to introduce prolines, which are 
known to break β-sheet structures.  
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PRIONS ARE INFECTIOUS AMYLOIDS 
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CREATING MUTANT VERSIONS OF THE SUP35 PRION GENE 
Introduced mutations were 
designed to hit at different 
points (residue 15, 20, 25) in the 
β-strands and potentially have 
greater/lesser effects on prion 
structure, stability, etc. 
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